about
Analysis of meiotic recombination in 22q11.2, a region that frequently undergoes deletions and duplicationsGESAP trial rationale and methodology: management of patients with suspected obstructive sleep apnea in primary care units compared to sleep unitsImpact of Obstructive Sleep Apnea on the Levels of Placental Growth Factor (PlGF) and Their Value for Predicting Short-Term Adverse Outcomes in Patients with Acute Coronary Syndrome.Association between Obstructive Sleep Apnea and Community-Acquired Pneumonia.Impact of OSA on biological markers in morbid obesity and metabolic syndrome.Blood pressure improvement with continuous positive airway pressure is independent of obstructive sleep apnea severityLong-term adherence to continuous positive airway pressure therapy in non-sleepy sleep apnea patients.Use of Ambulatory Blood Pressure Monitoring for the Screening of Obstructive Sleep Apnea.Characterization of the CPAP-treated patient population in Catalonia.Vitamin-D pathway genes and HIV-1 disease progression in injection drug users.Immunophenotype of vitamin D receptor polymorphism associated to risk of HIV-1 infection and rate of disease progression.Tagging long-lived individuals through vitamin-D receptor (VDR) haplotypes.The relationship between floppy eyelid syndrome and obstructive sleep apnoea.Vitamin D status and parathyroid hormone levels in patients with obstructive sleep apnea.Metabolic syndrome, insulin resistance and sleepiness in real-life obstructive sleep apnoea.Free fatty acids and the metabolic syndrome in patients with obstructive sleep apnoea.Rationale and methodology of the impact of continuous positive airway pressure on patients with ACS and nonsleepy OSA: the ISAACC Trial.Management of continuous positive airway pressure treatment compliance using telemonitoring in obstructive sleep apnoea.Gut epithelial barrier markers in patients with obstructive sleep apnea.Reply: Precision Medicine, Obstructive Sleep Apnea, and Refractory Hypertension.Intermittent Hypoxia-Induced Cardiovascular Remodeling Is Reversed by Normoxia in a Mouse Model of Sleep Apnea.What treatment wins in the battle against sleepiness?Impact of obstructive sleep apnea on the 24-h metabolic hormone profile.Effect of CPAP treatment on plasma high sensitivity troponin levels in patients with obstructive sleep apnea.The influence of obesity and obstructive sleep apnea on metabolic hormones.Plasma levels of neuropeptides and metabolic hormones, and sleepiness in obstructive sleep apnea.NADPH oxidase p22phox polymorphisms and oxidative stress in patients with obstructive sleep apnoea.Day-night variations in endothelial dysfunction markers and haemostatic factors in sleep apnoea.Non-synonymous polymorphism in the neuropeptide S precursor gene and sleep apnea.[Personalized medicine in sleep apnea: Towards a new paradigm of comprehensive disease management].Precision medicine: A modern odyssey.Reply: To PMID 25747162.Corneal biomechanical properties in floppy eyelid syndrome.Biomarkers of carcinogenesis and tumour growth in patients with cutaneous melanoma and obstructive sleep apnoea.Subcutaneous advanced glycation end-products and lung function according to glucose abnormalities: The ILERVAS Project.Assessing sleep health in a European population: Results of the Catalan Health Survey 2015.Intermittent Hypoxia Is Associated With High Hypoxia Inducible Factor-1α but Not High Vascular Endothelial Growth Factor Cell Expression in Tumors of Cutaneous Melanoma Patients.Acetylsalicylic Acid Prevents Intermittent Hypoxia-Induced Vascular Remodeling in a Murine Model of Sleep Apnea.Comparative analysis of predictive methods for early assessment of compliance with continuous positive airway pressure therapyErectile dysfunction in obstructive sleep apnea patients: A randomized trial on the effects of Continuous Positive Airway Pressure (CPAP)
P50
Q33280664-48A6C6C0-AE29-4141-9BD7-8FFDF61477B7Q33697733-AE7E210B-3123-4E37-A140-F086CD67A41CQ35941412-EB215497-E5BE-44AE-969E-CB35A61D4074Q35981116-F41A3D58-F87F-41A4-B5BA-DFB10E74539AQ37590178-CB1F2F9B-CF46-426D-BB7F-D45211B5CF29Q37649892-FF148A11-1EB1-419A-8185-0CAF3642E5C1Q40021558-BD63A31F-D8E2-4C2A-9968-D07F6E18528BQ41554129-67D04819-F352-4D8A-9360-27429ACCBABCQ41839283-DAAE3105-1770-4B58-B1E8-65782AD8454FQ42222162-ABE74C76-303F-4265-93F2-7E8704BE9EB2Q42966029-6DF89D47-70BB-4F85-B9DF-B9E5C30B24C5Q43090989-61D369BF-7378-47D0-8BD5-69C84AA70AC2Q43466887-B83CB77A-7893-4F4B-BA65-68957BDB5701Q43502008-C1F656A2-A13F-4A94-B887-9B07AB29A559Q43510158-E0BCE0C2-32EB-477F-B504-3E746124E2E9Q43958336-4D4875CB-5370-41D3-A1F6-268AE20A1E3FQ44418182-70D08D41-4459-46F9-8752-6470623CA5C7Q47765609-4EFC81F4-D354-4300-81D5-DD4C38804089Q47781218-A23F16EC-36BA-4A11-AEAE-667DD22CD790Q47891166-B3FA1B3C-A4C5-4A77-A6F3-FCDE4F69A055Q47892176-82714768-CF6C-4405-A47A-D1E6E238B37AQ47923454-F70A30DF-59CF-46AC-9A37-F61B31334F9BQ48104780-C88E821B-4452-49C9-AF6E-4C481B598AE1Q48108912-60E3E925-2353-4D66-A4F2-E8C8C4D2CBA2Q48283226-3AFB80EA-0FB1-4D1B-92C3-A26E68CCA259Q48284778-42FF664A-AD31-4EE7-BA64-8D0C1B41564EQ48286304-70778326-0E58-4038-A0F1-5EAC854D85BBQ48287717-D4DC2EE8-2ED2-43D1-9E7A-4F5C51452FB4Q48362324-58B232AA-0BD0-464D-B62E-B76EAD393892Q50226911-70DCA168-2C01-4FF3-A8C9-6A174C5DDDBAQ50244051-BABB6FD4-C350-423D-85AD-DC24013058B1Q50439131-DFC366F6-64A2-416F-B3CC-B107CD78894BQ50450469-7C219AFA-286C-48D1-82C5-7CBC91AC96AAQ52727780-C067DD46-EA61-4577-890A-00EF6E16DA96Q53688356-FED686F2-2DE2-4837-B59B-3AF70505B867Q54943422-AABC55C1-60E6-4284-8444-2F47A1A1CE4AQ55285485-8C1C8507-6818-4733-A4D1-AFCF5516BB1FQ55340704-C2DDFC1A-F4F7-4663-BB49-96AFF3C22032Q58725090-9742FAF7-A5C2-48F1-8CE9-34A029546426Q58796217-3747EBEF-8490-4B4F-86A8-886962760A09
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Manuel Sánchez de la Torre
@ast
Manuel Sánchez de la Torre
@en
Manuel Sánchez de la Torre
@es
Manuel Sánchez de la Torre
@nl
Manuel Sánchez de la Torre
@sl
type
label
Manuel Sánchez de la Torre
@ast
Manuel Sánchez de la Torre
@en
Manuel Sánchez de la Torre
@es
Manuel Sánchez de la Torre
@nl
Manuel Sánchez de la Torre
@sl
prefLabel
Manuel Sánchez de la Torre
@ast
Manuel Sánchez de la Torre
@en
Manuel Sánchez de la Torre
@es
Manuel Sánchez de la Torre
@nl
Manuel Sánchez de la Torre
@sl
P1053
B-5578-2009
P106
P1153
16242700100
P21
P31
P3829
P496
0000-0002-5695-348X